Bristol-Myers Squibb Company (BMY) Stock Price, News, Analysis

Technical Score (1D)

NEUTRAL

News Sentiment

BULLISH

Bristol‑Myers Squibb has issued a forecast for a solid second‑quarter revenue growth, driven by its oncology and immunology pipeline, which signals a potential earnings uptick that could set a positive tone for the remainder of the year. The guidance implies that the company expects a stronger second half, suggesting cumulative upside that may support the dividend payout and income strategy highlighted by analysts. The firm’s high‑yield dividend profile and stable payout reinforce its appeal to income‑focused investors, as noted in a 5.5‑hour‑ago commentary. The combination of robust guidance and attractive dividend yield may attract both growth‑oriented and defensive funds, especially after BMY’s recent reclassification into defensive indices. The index shift could increase institutional demand from portfolios that prioritize defensive exposure, potentially providing a buying catalyst. Traders should monitor the upcoming earnings release for confirmation of the Q2 revenue projections and any updates to the dividend policy. Watching the impact of the index reclassification on fund flows will also be key to gauge short‑term demand dynamics.

BMY|Company Info

Sector

Healthcare

Industry

Drug Manufacturers - General

Exchange

NYQ

Country

United States

Website

bms.com

Symbol

BMY

Description

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines. Its core business centers around providing treatments for a diverse range of therapeutic areas, including oncology, hematology, immunology, and cardiovascular diseases. The company's portfolio features prominent products such as Eliquis, Opdivo, and Orencia, addressing conditions like atrial fibrillation, various cancers, and rheumatoid arthritis. Bristol-Myers Squibb distributes its biopharmaceutical products to a wide network of healthcare providers, including wholesalers, hospitals, and pharmacies, ensuring patient access to its therapies worldwide. Founded in 1887, the company maintains its headquarters in Princeton, New Jersey, and continues to evolve its product offerings to address unmet medical needs.

BMY|Earnings Snapshot

Earnings Summary

Bristol‑Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and commercializing innovative medicines across oncology, hematology, immunology, and cardiovascular disease, with flagship products such as Eliquis, Opdivo, and Orencia. Operating within the drug manufacturers sector, the company generates revenue primarily through a diversified portfolio of high‑margin therapies distributed worldwide. In the last two quarters, BMY posted EPS of $1.63 in Q3 2025 and $1.26 in Q4 2025, both exceeding analyst estimates of $1.51554 and $1.1262 respectively, while revenue rose from $12.222 B to $12.502 B, reflecting modest top‑line growth; the preceding quarters saw EPS of $1.46 in Q2 2025 and $1.80 in Q1 2025, again beating expectations, with revenue oscillating around $12 B. Historically, BMY has maintained a consistent streak of earnings beats across six consecutive quarters, with revenue hovering near $12 B and a slight upward trend in EPS, indicating stable profitability and effective cost control. Recent news highlights a forecast of solid second‑quarter revenue growth driven by oncology and immunology pipelines, a high‑yield dividend profile, and a shift from growth to defensive indices, all of which could attract income‑focused investors; the company’s SLS009 AML trial progress and partnership with Arcus Biosciences also signal potential future revenue streams. Investors should watch for the upcoming Q2 2026 earnings release for confirmation of the projected revenue trajectory, any updates to dividend policy, and milestones in the SLS009 trial, as well as passive fund flows following the index reclassification, which may influence short‑term liquidity and valuation.

Read full report

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$1.61	-	-
Q1'26	$1.42	$1.58	+11.1%
Q4'25	$1.13	$1.26	+11.9%
Q3'25	$1.52	$1.63	+7.6%
Q2'25	$1.10	$1.46	+32.6%
Q1'25	$1.50	$1.80	+19.9%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q2'26	$11.8B	-	-
Q1'26	$10.9B	$11.5B	+5.2%
Q4'25	$12.4B	$12.5B	+0.8%
Q3'25	-	$12.2B	-
Q2'25	-	$12.3B	-
Q1'25	-	$11.2B	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

BMY Stock Snapshot

BMY is currently trading at $57.35, giving Bristol-Myers Squibb Company a market cap of 117.15B and a P/E ratio of 19.6. Today's range spans $56.93–$58.08, with shares opening at $57.79 and moving down $0.21 (0.4%) from the prior close. DailyIQ's technical score sits at 45/100 (HOLD) with a news sentiment reading of 73/100.

Over the past year BMY has traded between $42.52 and $62.89 - the current price is +34.9% off the 52-week low and -8.8% from the high. 36 analysts cover the stock with a Hold consensus and a mean 12-month target of $63.00 (range $40.00–$75.00), implying upside of +9.9%.

Neutral technical setups in large-cap Healthcare names are inherently unstable - they resolve. Right now, BMY (45/100, HOLD, price $57.35, in the upper portion of its 52-week range) is waiting for that resolution. Sentiment: bullish at 73/100. The current P/E ratio stands at 19.6. With 117.15B in market cap, the 52-week range of $42.52–$62.89 is where structural support and resistance live - and which one holds when the next catalyst hits will define the next trade.

Portfolio construction in Healthcare often uses large-cap names like BMY as tactical swing positions during neutral phases: cheap enough to overweight, liquid enough to exit quickly, and large enough to provide meaningful sector beta. The current 45/100 (HOLD) at $57.35 (in the upper portion of its 52-week range) and bullish sentiment (73/100) frame the position as a catalyst play within the $42.52–$62.89 annual range rather than a directional bet.

News Sentiment Analysis

Sentiment gathered from recent headlines

73/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Bristol‑Myers Squibb (BMY) forecasts a solid second quarter, citing robust pipeline and expanding H2 prospects. The company expects revenue growth driven by its oncology and immunology products. Analysts anticipate that the Q2 performance will set the stage for a stronger second half. Investors should monitor guidance releases and quarterly earnings for confirmation.

What did this article say?

BMY is highlighted as a high‑yield dividend stock for investors approaching retirement. The company offers a stable dividend payout, making it attractive for income‑focused portfolios. Its recent earnings support continued dividend growth, and the stock’s valuation remains attractive relative to peers. Traders should watch dividend announcements and earnings releases for potential catalyst.

What did this article say?

Recent index reclassification moved BMY from Russell growth benchmarks to the Russell 1000 Defensive and Value‑Defensive indices, potentially altering institutional exposure. At $57.54, the stock has shown modest short‑term gains—+1.95% over 7 days and +3.55% over 30 days—while a 90‑day decline indicates longer‑term weakness. The shift may prompt portfolio managers to adjust holdings to align with defensive mandates. Traders should assess how the new index composition could influence demand for BMY shares.

What did this article say?

Bristol Myers Squibb’s Foundation has extended its QUILS lung cancer early‑detection initiative beyond Kentucky to include Mississippi and Nevada, targeting regions with high incidence rates. The expansion positions BMY as a leader in public‑health oncology outreach and may improve early diagnosis rates in these states. The program’s success could serve as a blueprint for further state‑level implementations, potentially influencing future funding and regulatory support.

What did this article say?

Bristol‑Myers Squibb is slated to report its Q2 2026 earnings later this month. Wall Street analysts are forecasting a double‑digit decline in profit, reflecting concerns over pipeline and pricing pressures. The earnings release will provide clarity on revenue outlook and guidance for the remainder of the fiscal year. Traders should watch for any revisions to guidance that could affect valuation.

What did this article say?

No summary available yet for this article.

What did this article say?

Sellas Life Sciences’ SLS009 AML trial continues recruiting patients, using Venetoclax and Azacitidine—both sold by Bristol Myers Squibb—in combination with its investigational CDK9 inhibitor. The study targets high‑risk acute myeloid leukemia and is expected to complete primary endpoints in late 2026. The inclusion of BMY’s established agents underscores the drug’s positioning within a broader combination therapy landscape, potentially enhancing its clinical appeal. Traders should monitor enrollment progress, interim efficacy data, and any partnership discussions that could influence BMY’s drug utilization.

What did this article say?

Bristol‑Myers Squibb was removed from several Russell growth benchmarks in late June 2026 and added to the Russell 1000 Value‑Defensive and Russell 1000 Defensive indices. The reclassification signals that index providers now view BMY as a defensive, income‑oriented stock rather than a growth‑driven pharmaceutical name. The move aligns with BMY’s dividend profile and its strategy to manage patent expirations. Investors should assess how the new index placement may influence passive fund flows and the company’s risk‑return profile.

What did this article say?

Bristol‑Myers Squibb delivered a 29.2% year‑to‑date return, underscoring solid performance. Valuation metrics, however, present a mixed picture, balancing attractive earnings against price concerns. Investor focus remains on oncology and cardiology pipeline developments, with recent trial collaborations and regulatory reviews poised to influence future cash flows. The company’s exposure to pricing policy changes adds a layer of risk that could impact valuation further.

What did this article say?

Cantor Fitzgerald’s analyst Carter Gould reaffirmed a neutral stance on Bristol‑Myers Squibb (BMY) and kept the $54 price target unchanged. The rating reflects the company’s steady earnings outlook and the lack of new catalysts in the near term. Investors should note that the neutral view signals no immediate upside or downside expectation, but the target remains a benchmark for future performance.

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

No summary available yet for this article.

What did this article say?

BMY·Bristol-Myers Squibb Company

EPS

Revenue

BMY Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More